Magnitude of drug resistant shigellosis in Nepalese patients
,
Abstract
Background and Objectives: Shigella plays an important role as a causative organism of acute gastroenteritis, in children and others. Rapid emergence of antibiotic resistance warrants continuous monitoring of susceptibility pattern of bacterial isolates. We report here our findings about Shigella spp. isolates and their drug resistance patterns in Nepalese patients.
Materials and Methods: The study was conducted on 507 Nepalese patients with acute gastroenteritis attending outpatient and inpatient departments of Nepalgunj Medical college and teaching Hospital, Banke, Nepal from September 2011 to April 2013. Stool specimens were processed for isolation and identification of Shigella species following the standard microbiological methods while the disc diffusion test was used to determine antimicrobial resistance patterns of the recovered isolates at the central Laboratory of Microbiology.
Results: Sixty nine isolates were identified as Shigella species. S. flexneri, S. dysenteriae, S. boydii and S. sonnei accounted, respectively, for 42.03%, 27.54%, 21.74% and 8.70% of the total number of Shigella isolates. Resistance to nalidixic acid (95.65%), ampicillin (85.51%), co-trimoxazole (82.61%) and ciprofloxacin (47.83%) was observed. Among 69 isolates, 29 (42.03%) were from children aged 1-10 years and this group was statistically significant (P < 0.05), compared to the other age groups.
Conclusions: The study revealed endemicity of shigellosis with S. flexneri as the predominant serogroup in Nepalese patients. Children were at a higher risk of severe shigellosis. Nalidixic acid, ampicillin, co-trimoxazole and ciprofloxacin should not be used empirically as the first line drugs in treatment of shigellosis. Continuous local monitoring of resistance patterns is necessary for the appropriate selection of empirical antimicrobial therapy.
Shears P. Shigella infections. Ann Trop Med Parasitol 1996; 90: 105-114.
World Health Organization. Vaccine research and development: new strategies for accelerating Shigella vaccine development. Wkly Epidemiol Rec 1997; 72:73-80.
World Health Organization. Diarrhoeal disease due to Shigella disease. In: Vaccines, immunization and biologicals. Geneva: World Health Organization, 1998:1-5.
Handin RI (1998). Shigellosis. In: Gerald TK, Dennis JK- Harrison’s Principles of Internal Medicine, Vol-1,14th ed. New York: Mc Graw Hill Inc, PP. 957-959.
Iwalokun BA, Gbenle GO, Smith SI, Ogunledun A, Akinsinde KA, Omonigbehin EA. Epidemiology of Shigellosis in Lagos, Nigeria: trends in antimicrobial resistance. J Health Popul Nutr 2001; 19: 183-90.
Geo FB, Janet SB, Stepehn AM. Jawetz, Melnick, Adelberg’s (1998). Medical Microbiology, 21st ed. Appleton & Lange publishers, PP. 224-226.
Guyot A. Antibiotic resistance of Shigella in Monorovia, Liberia. J Trop Doc 1969; 26: 70-71.
Brito A, Nij B. Antibiotic resistance pattern and plasmid profiles for Shigella spp. isolated in Cordoba, Argentina. J Antimicrob Chemother 1994; 34: 253-259.
H Srinivasa, M Baijayanti, Y Raksha. Magnitude of drug resistant shigellosis: A report from Bangalore. Indian Journal of Medical Microbiology. 2009; 27: 358-360.
Subekti D, Oyofo BA, Tjaniadi P, Corwin AL, Larasati W, Putri M et al. Shigella spp. surveillance in Indonesia: the emergence or reemergence of S. dysenteriae. Emerg Infect Dis 2001; 7: 137-140.
Shahid NS, Rahaman MM, Haider K, Banu H, Rahman N. Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis 1985; 152: 1114-119.
Thong KL, Hoe CH, Koh YT, Yasim RM. Prevalence of multidrug-resistant Shigella isolated in Malaysia. J Health Popul Nutr 2002; 20: 356-8.
Wilson G, Easow JM, Mukhopadhyay C, Shivananda PG. Isolation and antimicrobial susceptibility of Shigella from patients with acute gastroenteritis in Western Nepal. Indian J Med Res 2006; 123: 145-150.
Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana B, Lemmens P, Vandeven J. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increased frequency of multiple resistance. Diagn Microbiol Infect Dis 1997; 28: 165-171.
Mata LJ, Gangarosa EJ Cáceres A, Perera DR, Mejicanos ML. Epidemic Shiga bacillus dysentery in Central America. 1. Etiologic investigations in Guatemala,1969. J Infect Dis 1970; 122: 170-180.
Essers B, Burnens AP, Lanfranchini FM, Somaruga SG, von Vigier RO, Schaad UB et al. Acute community- acquired diarrhea requiring hospital admission in Swiss children. Clin Infect Dis 2000; 31: 192-196.
Torres ME, Pírez MC, Schelotto F, Varela G, Parodi V, Allende F et al. Etiology of children’s diarrhea in Montevideo, Uruguay: associated pathogens and unusual isolates. J Clin Microbiol 2001; 39: 2134-219.
Leslie C, Albert B, Max S (1998). Escherichia and Shigella. In: Topley & Wilson’s Microbiology and Microbial Infections, 9th ed. Arnold Press, Great Britain.948-50.
Niyogi SK. Shigellosis. J Microbiol 2005; 43: 33-43.
Cowan ST. (1974) Manual for identification of medical bacteria. 2d ed. London: Cambridge University Press, PP. 104-105.
Bauer AW, Kirby WMM, sherris JC, Turck M. Antibiotic susceptibility testing by a standard single disc method. Am J Clin Pathol 1966; 45: 493-496.
Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD,Swerdlow DL, Sansonetti PJ et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77: 651-666.
Bhattacharya S, Basudha Khanal S, Bhattarai N R, Das.
Prevalence of Shigella species and their antimicrobial resistance patterns in Eastern Nepal. J health popul nutr 2005; 23: 339-342.
Niyogi SK, Mitra U, Dutta P. Changing patterns of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta,India. Jpn J Infect Dis 2001; 54: 121-122.
Jesudason MV. Shigella isolation in Vellore, South India (1997-2001). Indian J Med Res 2002; 115: 11-13.
Zaman K, Yunus M, Baqui AH, Hossain KMB.Surveillance of shigellosis in rural Bangladesh: a 10 years review. J Pak Med Assoc 1991; 41: 75-78.
Bhattacharya D, Sugunan AP, Bhattacharjee H, Thamizhmani R, Sayi DS, Thanasekaran, et al. Antimicrobial resistance in Shigella - rapid increase & widening of spectrum in Andaman Islands, India. Indian J Med Res 2012; 135: 365-370.
Shrestha CD,Malla S, Maharjan L. Multi drug resistant Shigella species in Nepal, a retrospective study conducted at National Public Health Laboratory (NPHL),1999 to 2002. J Nepal Health Res Counc 2002; 4: 365-370.
Thapa BR, Ventkateswarlu K, Malik AK, Panigrahi D. Shigellosis in children from North India: a clinicopathological study. J Trop Pediatr 1995; 41:303-307.
Bennish ML, Salam MA, Hossain MA, Myaux J,Khan EH, Chakraborty J et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis. 1992; 14: 1055-1060.
Sack BR, Rahman M, Yunus M, Khan HE. Antimicrobial resistance in organisms causing diarrheal disease. Clin Infect Dis 1997; 24: 102-105.
Khan AI, Huq S, Malek MA, Hossain MI, Talukder KA, Faruque ASG et al. Shigella serotypes among hospitalized patients in urban Bangladesh and their antimicrobial resistance. Epidemiol Infect 2004; 132:773-777.
Khan WA, Seas C, Dhar U, Salam MA, Bennish ML.Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind,randomized, controlled trial. Ann Intern Med 1997; 126: 697-703.
Gharibi O, Zangene S, Mohammadi N, Mirzaei K, Karimi A, Gharibi A, et al. Increasing antimicrobial resistance among Shigella isolates in the Bushehr, Iran. Pak J Biol Sci 2012; 15: 156-159.
Gizachew Y, Challa N, Afework K. A five-year antimicrobial resistance pattern observed in Shigella species isolated from stool samples in Gondar University Hospital, northwest Ethiopia. Ethiop J Health Dev 2006;20: 194-198.
Iwalokun BA, Gbenle GO, Smith SI, Ogunledun A, Akinsinde KA, Omonigbehin EA. Epidemiology of Shigellosis in Lagos, Nigeria:Trends in Antimicrobial Resistance. J Health Popul Nutr 2001; 19: 183-190.
Guidelines for the Control of Shigellosis, including epidemics due to Shigella dysenteriae type1.Geneva: WHO; 2005.[accessed on September 22, 2010].
Naheed A,Kalluri P,Talukder KA, Faruque AS, Khatun F, Nair GB et al. Fluoroquinolone & resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis 2004; 4: 607-608.
Hirose K, Terajima J, Izumiya H, Tamura K, Arakawa E, Takai N, et al. Antimicrobial susceptibility of Shi- gella sonnei isolates in Japan and molecular analysis of S.sonnei isolates with reduced susceptibility to fluoro- quinolones. Antimicrob Agents Chemother 2005; 49:1203-1205.
Roy S, Bhattacharya D, Thanasekaran K, Ghosh AR, Manimunda SP, Bharadwaj AP, et al. Emergence of fluoroquinolone resistance in Shigella isolated from Andaman & Nicobar Islands, India. Indian J Med Res 2010; 131: 720-722.
| Files | ||
| Issue | Vol 5 No 4 (2013) | |
| Section | Articles | |
| Keywords | ||
| Antimicrobial resistance Nepal Shigella gastroenteritis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
